STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TRAMADOL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRAMADOL HCL	QDOLO, TRAMADOL HCL		48598	GPI-14 (65100095102005)	

GUIDELINES FOR USE

1. Is the request for the management of pain and the patient meets **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient's pain is severe enough to require an opioid analgesic and alternative treatments are inadequate
   - The patient had a trial of or contraindication to generic tramadol IR tablet or a generic tramadol with acetaminophen product
   - The patient is unable to take oral solid formulations of tramadol or tramadol with acetaminophen (e.g., difficulty swallowing)

   If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #80mL per day.**
   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **TRAMADOL (Qdolo)** requires the following rule(s) be met for approval:
   A. The request is for the management of pain
   B. You are 18 years of age or older
   C. Your pain is severe enough to require an opioid analgesic (type of pain medication) and alternative treatments are inadequate
   D. You had a trial of or contraindication (harmful for) to generic tramadol immediate-release (IR) tablet or a generic tramadol with acetaminophen product
   E. You are unable to take oral solid formulations of tramadol or tramadol with acetaminophen (such as with difficulty swallowing)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TRAMADOL

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Qdolo.

REFERENCES

- Qdolo [Prescribing Information]. Athens, GA: Athena Bioscience, LLC; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 03/14/22
Created: 02/21
Client Approval: 02/22
P&T Approval: 01/21